35,278 Shares in Celldex Therapeutics, Inc. (CLDX) Purchased by Cubist Systematic Strategies LLC
Cubist Systematic Strategies LLC acquired a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 35,278 shares of the biopharmaceutical company’s stock, valued at approximately $101,000.
Several other institutional investors and hedge funds have also recently bought and sold shares of CLDX. OxFORD Asset Management LLP bought a new stake in shares of Celldex Therapeutics in the 3rd quarter worth $122,000. Voya Investment Management LLC raised its stake in shares of Celldex Therapeutics by 17.4% in the 2nd quarter. Voya Investment Management LLC now owns 50,535 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 7,499 shares in the last quarter. BlueCrest Capital Management Ltd bought a new stake in shares of Celldex Therapeutics in the 2nd quarter worth $158,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Celldex Therapeutics in the 3rd quarter worth $242,000. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Celldex Therapeutics by 27.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 99,535 shares of the biopharmaceutical company’s stock worth $246,000 after buying an additional 21,355 shares in the last quarter. 52.46% of the stock is currently owned by institutional investors.
A number of analysts have recently commented on CLDX shares. Cantor Fitzgerald reissued a “buy” rating and issued a $9.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, September 26th. WBB Securities reaffirmed a “buy” rating and set a $10.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, December 6th. HC Wainwright reaffirmed a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday, November 7th. Finally, BidaskClub raised Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, January 5th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. Celldex Therapeutics presently has an average rating of “Hold” and a consensus price target of $7.05.
Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.07. The company had revenue of $3.90 million for the quarter, compared to analyst estimates of $1.30 million. Celldex Therapeutics had a negative return on equity of 46.94% and a negative net margin of 1,088.58%. Celldex Therapeutics’s revenue for the quarter was up 77.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.29) earnings per share. equities research analysts predict that Celldex Therapeutics, Inc. will post -0.93 EPS for the current fiscal year.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.